Azole Resistance in Candida glabrata

Candida infections have increased due to the growth and expansion of susceptible patient populations. The azole fluconazole is the most widely prescribed antifungal, but rising rates of clinical resistance among Candida glabrata isolates have greatly limited its utility. A better understanding of th...

Full description

Saved in:
Bibliographic Details
Published inCurrent Infectious Disease Reports Vol. 18; no. 12; p. 41
Main Authors Whaley, Sarah G., Rogers, P. David
Format Journal Article Book Review
LanguageEnglish
Published New York Springer US 01.12.2016
Springer Nature B.V
Subjects
Antimicrobial Development and Drug Resistance (A Pakyz
Bacteria
Drug resistance
Infections
Infectious Diseases
Medicine
Medicine & Public Health
Section Editor
Topical Collection on Antimicrobial Development and Drug Resistance
Resistance
Azole
Pdr1
Candida Glabrata
Online AccessGet full text

Cover

More Information
Summary:Candida infections have increased due to the growth and expansion of susceptible patient populations. The azole fluconazole is the most widely prescribed antifungal, but rising rates of clinical resistance among Candida glabrata isolates have greatly limited its utility. A better understanding of the mechanisms of azole antifungal resistance will provide information needed to overcome this clinical problem and reclaim this antifungal class as an option for empiric treatment of Candida infections. By far, the most frequent mechanism of azole resistance in C. glabrata is the overexpression of multidrug transporters due to activating mutations in the gene encoding transcription factor Pdr1. In this review, we will discuss the molecular and genetic basis of azole resistance in C. glabrata with particular attention given to the most recent discoveries in this field.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1523-3847
1534-3146
DOI:10.1007/s11908-016-0554-5